23 related articles for article (PubMed ID: 38485235)
1. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis.
Kang S; Yin J
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):653-659. PubMed ID: 38506058
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.
Li W; Wan L
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):671-678. PubMed ID: 38594905
[TBL] [Abstract][Full Text] [Related]
3. Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer.
Zribi A; Al Riyami K; Al Zahibi HS; Burney IA
Sultan Qaboos Univ Med J; 2024 May; 24(2):293-297. PubMed ID: 38828252
[TBL] [Abstract][Full Text] [Related]
4. RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Riedinger CJ; Barrington DA; Nagel CI; Khadraoui WK; Haight PJ; Tubbs C; Backes FJ; Cohn DE; O'Malley DM; Copeland LJ; Chambers LM
Gynecol Oncol; 2024 Apr; 183():78-84. PubMed ID: 38554477
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.
Wei J; Xu K; Lin Y; Liu Q; Zhou C; Zhang P; Ma R; Zhang M; Zhang L; Li X
Int J Clin Pharm; 2024 May; ():. PubMed ID: 38814514
[TBL] [Abstract][Full Text] [Related]
6. Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
Nierengarten MB
Cancer; 2024 Jul; 130(13):2246. PubMed ID: 38849630
[No Abstract] [Full Text] [Related]
7. Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
Nierengarten MB
Cancer; 2024 Jul; 130(13):2245. PubMed ID: 38849650
[No Abstract] [Full Text] [Related]
8. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China.
Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S
J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL
Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Ackroyd SA; Huang ES; Kurnit KC; Lee NK
Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
